Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AC Immune SA (NASDAQ: ACIU) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. AC Immune files annual reports on Form 20-F and furnishes current reports on Form 6-K, which together offer insight into its clinical-stage biopharmaceutical operations focused on precision prevention of neurodegenerative diseases.
Through its 6-K submissions, AC Immune furnishes interim condensed consolidated financial statements prepared under IFRS, management’s discussion and analysis of financial condition and results of operations, and press releases covering clinical and corporate developments. Examples include reports on interim Phase 2 data for the anti-alpha-synuclein active immunotherapy ACI-7104.056 in Parkinson’s disease, strategic pipeline refocusing and workforce reductions, and quarterly cash position and loss figures.
Investors can use these filings to track how AC Immune funds and prioritizes its programs, including active immunotherapies such as ACI-24.060 and ACI-35.030, small-molecule candidates like the NLRP3 inhibitor ACI-19764, and diagnostic PET tracers such as ACI-19626 and ACI-15916. Governance-related filings, including annual general meeting results, board and committee elections, compensation approvals and auditor reappointments, are also furnished on Form 6-K and incorporated by reference into the company’s shelf registration statements.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR, and AI-powered tools can help summarize lengthy 20-F and 6-K materials, highlight key risk factors, and surface important changes in clinical, financial or governance disclosures. This allows users to quickly understand how AC Immune’s regulatory reporting reflects the evolution of its neurodegeneration-focused pipeline and collaboration agreements.
AC Immune SA Chief Executive Officer Andrea Pfeifer sold 10,000 shares of the company’s stock in an open-market transaction. The amended filing clarifies that a prior report mistakenly showed this activity as a purchase and now correctly records it as a sale.
The shares were sold at a weighted average price of $3.1425, with individual trade prices ranging from $3.05 to $3.19. After the sale, Pfeifer directly owns 3,830,288 shares, including 1,921,005 common shares underlying outstanding restricted share units, and also has indirect ownership of 14,000 shares held by her spouse.
AC Immune SA Chief Executive Officer Andrea Pfeifer reported an open-market purchase of 10,000 common shares on April 15, 2026 at a weighted average price of $3.1425 per share, with individual trades ranging from $3.05 to $3.19.
Following this transaction, she directly owns 3,830,288 shares, which include 1,921,005 common shares underlying outstanding restricted share units. In addition, 14,000 shares are reported as indirectly owned through her spouse.
Andrea Pfeifer reports intent to sell 10,000 common shares. The Form 144 lists 10,000 shares with an aggregate value of $31,900 and identifies Morgan Stanley Smith Barney LLC as the broker. The filing also records 10b5-1 sales of 10,000 shares on 03/16/2026 for $31,966 and 10,000 shares on 02/17/2026 for $28,693. A 10,000-share block is noted as issuable from previously exercised options dated 06/01/2012.
AC Immune SA has amended its Morphomer® Tau license and collaboration agreement with Eli Lilly and Company to continue joint research and development of Tau aggregation inhibitor small molecules for potential treatment of Alzheimer’s disease and other neurodegenerative diseases.
Under the amendment, AC Immune will receive a CHF 10 million upfront payment and an additional milestone payment upon Phase 1 dosing, alongside previously announced milestones. AC Immune remains eligible for over CHF 1.7 billion in further development, regulatory and commercial milestones, plus tiered low double‑digit royalties on future sales. The company expects to start IND‑enabling studies for new Tau Morphomer candidates imminently.
AC Immune SA director Martin Zuegel filed an initial ownership report showing equity interests in the company. He holds share options over 52,577 and 32,061 common shares, each with an exercise price of $1.8400 per share and an expiration date of June 17, 2035. One option grant will fully vest on June 17, 2026, while the other will vest annually in three equal installments beginning on June 17, 2026. He also directly holds 38,272 common shares, which reflect common shares underlying outstanding restricted share units.
AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position. He directly holds 141,120 common shares, which include 136,620 common shares underlying outstanding restricted share units. In addition, he reports multiple share options over common shares with exercise prices between $2.03 and $9.50 per share and expiration dates from July 2028 through December 2035. Some options are already fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026, providing a staggered schedule of potential future share deliveries.
AC Immune SA’s Chief Financial Officer Christopher James Roberts has filed an initial statement of holdings. He reports direct ownership of 155,382 common shares, which the footnotes state includes 109,564 common shares underlying outstanding restricted share units. He also reports a series of share options to buy common shares with exercise prices ranging from 2.32 to 6.88 and expirations between 2029 and 2035. One option grant is fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026.
AC Immune SA director Monika Buetler filed an initial statement of beneficial ownership, detailing existing share and option positions. She reports direct ownership of 53,905 common shares, which includes 52,905 common shares underlying outstanding restricted share units. This filing does not show new buying or selling activity.
Buetler also holds several share options over AC Immune common shares with different exercise prices and maturities. These include options over 14,310 shares at an exercise price of 5.3100 that are fully vested and expire on December 9, 2031, and options over 56,204 shares at an exercise price of 3.1500 expiring on June 23, 2032. She further holds options over 39,823 shares at 2.1500 expiring June 23, 2033, and 15,501 shares at 4.2300 expiring June 30, 2034. Another option covers 46,392 shares at 1.8400 and will fully vest on June 17, 2026, with expiration on June 17, 2035. Together, these positions describe her current equity-based exposure to AC Immune, rather than recent market transactions.
AC Immune SA director Roy Ervin Twyman reported his initial holdings on a Form 3. He directly holds 75,988 common shares, including 49,988 common shares underlying outstanding restricted share units. He also holds multiple share options over common shares with exercise prices between $1.84 and $7.23, expiring from 2029 through 2035.
According to the footnotes, at least one share option grant is fully vested and another will fully vest on June 17, 2026, highlighting a mix of already exercisable and time-based equity awards.
AC Immune SA director Renee Aguiar‑Lucander has filed an initial ownership report. The filing shows direct ownership of 34,568 Common Shares. She also holds two share option awards, each exercisable at $1.8400 per share and expiring on June 17, 2035, covering 43,299 and 32,061 underlying Common Shares.
According to the footnotes, the 43,299-share option will fully vest on June 17, 2026, while the 32,061-share option vests in three equal annual installments beginning on that same date. This Form 3 records her starting equity position as a director rather than reporting new market transactions.